PsiOxus said it named Dr. Charles Morris as its chief development officer and Karen LaRochelle as its chief business officer.
Morris comes from ImmunoGen, where he was chief development officer, bringing its lead candidate to Phase III development. Most recently, LaRochelle was the executive director of global business development at Bristol Myers-Squibb. She worked as a consultant to PsiOxus and established a clinical collaboration between the 2 companies for Bristol Myer’s nivolumab and PsiOxus’ enadentucirev in solid tumors.
Oxford, U.K.-based PsiOxus also said it reorganized its executive team, promoting Dr. Brian Champion, formerly senior vice president for R&D, to chief scientific officer. Former CSO Dr. Kerry Fisher was named founding scientist and a member of the company’s scientific advisory board. COO Priya Mande was also named an executive director.
CFO Theodora Harold is stepping down to pursue other opportunities.
“I am delighted to welcome Karen and Charlie to reinforce our executive team at this key stage of our growth,” CEO Dr. John Beadle said in prepared remarks. “Charlie brings over 2 decades of oncology development expertise at a time that we are expanding our clinical stage activities in both the U.S. and Europe, whilst Karen’s impressive track record of over 50 successful transactions will be critical in achieving our portfolio strategy, which will be built upon a series of strategic collaborations using our T-SIGn platform. It is with sadness that we say goodbye to Theo and wish her every success in her new endeavors.”